Author Topic: (Abst.) Inebilizumab (MEDI-551)--results from phase 1 study  (Read 82 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9419
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Inebilizumab (MEDI-551)--results from phase 1 study
« on: February 01, 2019, 09:40:35 pm »

Abstract, "Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of MS:  Results from a phase 1, randomised, placebo-controlled, escalating  intravenous and subcutaneous dose study" in Multiple Sclerosis Journal (February 1, 2019; first published November 2017):

https://journals.sagepub.com/doi/abs/10.1177/1352458517740641
MS Speaks--online for 16 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
95 Views
Last post November 16, 2016, 08:37:33 am
by agate
0 Replies
88 Views
Last post September 20, 2017, 02:55:23 pm
by agate
0 Replies
19 Views
Last post December 02, 2020, 03:35:02 pm
by agate
0 Replies
23 Views
Last post July 18, 2021, 09:27:34 pm
by agate
1 Replies
15 Views
Last post January 25, 2023, 02:32:29 pm
by agate